FDA is allowing ZYN nicotine pouches, a tobaccoless product that has soared in popularity since in recent years, to make the claim that its products are safer than cigarettes.
FDA’s Oncology Center of Excellence released its 2025 Annual Report.
FDA allows ZYN nicotine pouches to make marketing claim: ZYN is safer than cigarettes
Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
YOU MAY BE INTERESTED IN
FDA approved Trodelvy (sacituzumab govitecan-hziy), a first-in-class Trop-2-directed antibody-drug conjugate, for the first-line treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer.
FDA approved Tregzi, the first regulatory T (Treg) cell-based immunotherapy for improving chronic graft-versus-host disease-free survival in adult patients with blood cancers undergoing allogeneic hematopoietic stem cell transplantation.
FDA has approved expanded use of Casgevy (exagamglogene autotemcel) for the treatment of people ages 2 years and older with either sickle cell disease with recurrent vaso-occlusive crises or transfusion-dependent beta thalassemia.
In this week’s episode of The Cancer Letter Podcast, Paul Goldberg, editor and publisher of The Cancer Letter, and Sara Willa Ernst, reporter, break down HHS’ latest vision for the future: Operation Trailblazer.
An FDA advisory panel has recommended approval of Moderna’s mRNA-based flu vaccine, mFlusiva, for adults ages 50-64, and adults 65 and older, if a specific condition is met.
